ARCTURUS THERAPEUTICS HOLDINGS INC. Research and Development Expense
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Research and Development Expense of $17.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. research and development expense for the quarter ending 2026-06-30 was $17.52M, a 40.79% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. research and development expense for the quarter ending 2026-03-31 was $21.53M, a 38.31% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. research and development expense for the quarter ending 2025-12-31 was $24.48M, a 44.09% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. research and development expense for the quarter ending 2025-09-30 was $23.27M, a 40.55% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. research and development expense for fiscal 2025 was $112.21M, a 42.50% decline from fiscal 2024.
- ARCTURUS THERAPEUTICS HOLDINGS INC. research and development expense for fiscal 2024 was $195.16M, a 1.57% increase from fiscal 2023.
- ARCTURUS THERAPEUTICS HOLDINGS INC. research and development expense for fiscal 2023 was $192.13M, a 30.04% increase from fiscal 2022.
- ARCTURUS THERAPEUTICS HOLDINGS INC. research and development expense for fiscal 2022 was $147.75M, a 14.97% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.52M 10-Q · filed 2026-08-06 | $39.04M 10-Q · filed 2026-08-06 | $63.52M derived: sum of 3 quarters · filed 2026-08-06 | $86.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $21.53M 10-Q · filed 2026-05-07 | $46.00M derived: sum of 2 quarters · filed 2026-05-07 | $69.27M derived: sum of 3 quarters · filed 2026-05-07 | $98.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $24.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $47.74M derived: sum of 2 quarters · filed 2026-03-03 | $77.32M derived: sum of 3 quarters · filed 2026-08-06 | $112.21M 10-K · filed 2026-03-03 |
| 2025-09-30 | $23.27M 10-Q · filed 2025-11-12 | $52.84M derived: sum of 2 quarters · filed 2026-08-06 | $87.74M 10-Q · filed 2025-11-12 | $131.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $29.58M 10-Q · filed 2026-08-06 | $64.47M 10-Q · filed 2026-08-06 | $108.25M derived: sum of 3 quarters · filed 2026-08-06 | $147.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $34.89M 10-Q · filed 2026-05-07 | $78.67M derived: sum of 2 quarters · filed 2026-05-07 | $117.81M derived: sum of 3 quarters · filed 2026-05-07 | $176.48M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $43.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $82.91M derived: sum of 2 quarters · filed 2026-03-03 | $141.58M derived: sum of 3 quarters · filed 2026-03-03 | $195.16M 10-K · filed 2026-03-03 |
| 2024-09-30 | $39.13M 10-Q · filed 2025-11-12 | $97.80M derived: sum of 2 quarters · filed 2025-11-12 | $151.38M 10-Q · filed 2025-11-12 | $188.00M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $58.67M 10-Q · filed 2025-08-11 | $112.24M 10-Q · filed 2025-08-11 | $148.86M derived: sum of 3 quarters · filed 2026-03-03 | $199.94M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $53.57M 10-Q · filed 2025-05-12 | $90.19M derived: sum of 2 quarters · filed 2026-03-03 | $141.27M derived: sum of 3 quarters · filed 2026-03-03 | $193.94M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $36.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $87.70M derived: sum of 2 quarters · filed 2026-03-03 | $140.37M derived: sum of 3 quarters · filed 2026-03-03 | $192.13M 10-K · filed 2026-03-03 |
| 2023-09-30 | $51.08M 10-Q · filed 2024-11-07 | $103.75M derived: sum of 2 quarters · filed 2024-11-07 | $155.51M 10-Q · filed 2024-11-07 | $182.49M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $52.67M 10-Q · filed 2024-08-05 | $104.44M 10-Q · filed 2024-08-05 | $131.42M derived: sum of 3 quarters · filed 2025-03-06 | $169.10M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $51.77M 10-Q · filed 2024-05-08 | $78.75M derived: sum of 2 quarters · filed 2025-03-06 | $116.44M derived: sum of 3 quarters · filed 2025-03-06 | $154.63M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $26.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $64.67M derived: sum of 2 quarters · filed 2025-03-06 | $102.86M derived: sum of 3 quarters · filed 2025-03-06 | $147.75M 10-K · filed 2025-03-06 |
| 2022-09-30 | $37.69M 10-Q · filed 2023-11-14 | $75.88M derived: sum of 2 quarters · filed 2023-11-14 | $120.77M 10-Q · filed 2023-11-14 | $153.40M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $38.19M 10-Q · filed 2023-08-07 | $83.08M 10-Q · filed 2023-08-07 | $115.72M derived: sum of 3 quarters · filed 2023-08-07 | $161.11M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $44.89M 10-Q · filed 2023-05-09 | $77.53M derived: sum of 2 quarters · filed 2023-05-09 | $122.92M derived: sum of 3 quarters · filed 2023-05-09 | $168.60M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $32.63M 10-K · filed 2022-03-01 | $78.03M derived: sum of 2 quarters · filed 2022-11-09 | $123.71M derived: sum of 3 quarters · filed 2022-11-09 | $173.76M 10-K · filed 2024-03-14 |
| 2021-09-30 | $45.40M 10-Q · filed 2022-11-09 | $91.08M derived: sum of 2 quarters · filed 2022-11-09 | $141.13M 10-Q · filed 2022-11-09 | $165.41M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $45.68M 10-Q · filed 2022-08-09 | $95.73M 10-Q · filed 2022-08-09 | $120.02M derived: sum of 3 quarters · filed 2022-08-09 | $137.71M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $50.05M 10-Q · filed 2022-05-09 | $74.34M derived: sum of 2 quarters · filed 2022-05-09 | $92.03M derived: sum of 3 quarters · filed 2022-05-09 | $99.98M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $24.29M 10-K · filed 2022-03-01 | $41.98M derived: sum of 2 quarters · filed 2022-03-01 | $49.93M derived: sum of 3 quarters · filed 2022-03-01 | $57.85M 10-K · filed 2022-03-01 |
| 2020-09-30 | $17.70M 10-K · filed 2022-03-01 | $25.64M derived: sum of 2 quarters · filed 2022-03-01 | $33.56M 10-Q · filed 2021-11-09 | $45.55M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $7.94M 10-K · filed 2022-03-01 | $15.86M 10-Q · filed 2021-08-10 | $27.86M derived: sum of 3 quarters · filed 2022-03-01 | $34.91M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $7.92M 10-K · filed 2022-03-01 | $19.91M derived: sum of 2 quarters · filed 2022-03-01 | $26.96M derived: sum of 3 quarters · filed 2022-03-01 | $34.23M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $11.99M 10-K · filed 2021-03-01 | $19.05M derived: sum of 2 quarters · filed 2021-03-01 | $26.32M derived: sum of 3 quarters · filed 2021-03-01 | $33.64M 10-K · filed 2022-03-01 |
| 2019-09-30 | $7.05M 10-K · filed 2021-03-01 | $14.32M derived: sum of 2 quarters · filed 2021-03-01 | $21.65M 10-Q · filed 2020-11-09 | $26.49M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $7.27M 10-K · filed 2021-03-01 | $14.59M 10-Q · filed 2020-08-10 | $19.44M derived: sum of 3 quarters · filed 2021-03-01 | $23.41M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $7.32M 10-K · filed 2021-03-01 | $12.17M derived: sum of 2 quarters · filed 2021-03-01 | $16.14M derived: sum of 3 quarters · filed 2021-03-01 | $20.36M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $4.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $8.82M derived: sum of 2 quarters · filed 2021-03-01 | $13.04M derived: sum of 3 quarters · filed 2021-03-01 | $16.98M 10-K · filed 2021-03-01 |
| 2018-09-30 | $3.97M 10-Q · filed 2019-11-08 | $8.19M derived: sum of 2 quarters · filed 2019-11-08 | $12.13M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $4.22M 10-Q · filed 2019-08-14 | $8.17M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |